samedan logo
 
 
spacer
home > epc > autumn 2018 > right first and every time
PUBLICATIONS
European Pharmaceutical Contractor

Right First and Every Time

In recent years, a number of regulatory agencies, scientific bodies, and healthcare organisations have introduced many initiatives to improve the effectiveness and quality of clinical research. However, challenges are still evident when it comes to balancing safety and efficiency in clinical research. Thus, it has been repeatedly stated that better quality management and a different approach is needed urgently. Evolution needs to be driven for safer, more effective clinical research based on principles of minimising harm, removing waste, and managing variation. This requires a more systematic approach.

Good Clinical Practice (GCP) guidelines are simply not enough to ensure safety nowadays. One of the reasons for this is that these are regulations that offer the workflow of documentation and the structure of clinical trials, but the control over how people are implementing them is far too low. To address this challenge, developing standardisation processes of the investigator sites and a database of these accredited sites came into effect in many clinical trials. This standardisation covers all aspects of documentation, patient engagement, and professional qualification of the organisation, where the clinical trials are going to be conducted. Instead of focussing only on the way the site follows ICH GCP regulation, the efficiency profile of the investigator sites will need to be ensured.

Appropriate, proportionate standards that focus on the things that matter are necessary. Beyond any revisions to the existing guidelines or the creation of new sets of guidance, wider cultural change is required to ensure that guidance is implemented appropriately.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Suzanne Pavon is Chief Quality and Compliance Officer, Executive Vice President of Quality Management, Corporate Compliance, and Legal at TFS. Suzanne is an entrepreneurial leader and senior executive with over 20 years’ global experience in the pharmaceutical, biotechnology, and CRO industry. Previous roles include a number of senior leadership positions in quality management, compliance, and clinical operations. She has worked at Novartis, Clinigen, uniQure, Teva, Sanofi, and Genzyme, including five years working at Mayo Clinic, US, and the King Hussain Cancer Center, Jordan. Suzanne is a graduate of Philadelphia University, US, and Harvard School of Public Health, US, and has earned a PhD in oncology, a PharmD, and Certified Professional in Healthcare Quality status.
spacer
Dr Suzanne Pavon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

2019 Pharmapack Awards

Pharmapack Europe have announced entries for the 2019 Pharmapack Awards are now open across both the ‘Exhibitor Innovation’ and ‘Health Products’ categories with a closing date of 30th November 2018. The Health Products category will include two winners with one for Patient-Centric Design – which is launched in partnership with HCPC Europe (Healthcare Compliance Packaging Council of Europe) – and a second introduced alongside Adelphe for Eco-design in health packaging and drug delivery devices. Pharmapack Europe have also announced that they’re accepting applications for the start-up hub which provides young start-up companies servicing the pharma industry with the benefit of valuable networking and learning opportunities at half the price of a regular stand.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 
Industry Events

14th Annual Biomarkers Congress

21-22 February 2019, Manchester Central Convention Complex, UK

Oxford Global is proud to present for the 14th year our flagship Biomarkers Congress, taking place 21 – 22 February 2019 in Manchester, UK. An updated programme ensures you will benefit from talks on the latest strategies and technologies impacting growth in the biomarker industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement